Testing a new drug for B-cell lymphoma that has returned
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental drug (ICP-248) alone or with another antibody therapy for people with B-cell lymphomas that have returned or not responded to treatment. It aims to see if the drug is safe and if it can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of B-cell lymphoma (like CLL/SLL or MCL) that has come back or not responded to at least two prior treatments, and one of those treatments included a BTK inhibitor.
- You are able to take care of yourself (ECOG score 0-1) and your doctor expects you to live at least 6 more months.
- Your major organs (blood, liver, kidneys, heart, lungs) are working well enough for this trial.
- You are not pregnant and agree to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase (Phase 1) study tests ICP-248 in people with certain B-cell cancers that have come back (relapsed) or did not respond to prior treatment (refractory). The goal is to learn the safest dose and whether it can help shrink or control the cancer.
This trial tests a new drug called ICP-248 for people with mantle cell lymphoma that has returned or not responded to previous treatments. It aims to see if the drug is safe and effective.
This trial tests two new oral medications (ICP-248 and Orelabrutinib) together as a first treatment for people with CLL or SLL. The goal is to see if this combination works better than current options and is safe for newly diagnosed patients.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
This trial tests an investigational drug called ICP-490 for people with non-Hodgkin lymphoma that has come back or hasn't improved after prior treatments. The study checks if the drug is safe, tolerable, and effective.
Hear when a new Mature B-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.